AI in Clinical Trials Market is Segmented By Offering (Software, Services), By Technology (Machine learning, Deep learning, Supervised), By Applicatio....
Market Size in USD
CAGR16.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 16.2% |
Market Concentration | High |
Major Players | Aegle Therapeutics, Coya Therapeutics, Evox Therapeutics, Nano 24, ReNeuron |
The Global AI in Clinical Trials Market is estimated to be valued at USD 1.52 Billion in 2024 and is expected to reach USD 4.31 Billion by 2031, growing at a compound annual growth rate (CAGR) of 16.2% from 2024 to 2031. AI has the potential to optimize clinical trials by improving patient recruitment and retention, trial design, patient monitoring and more. The increased adoption of AI solutions in clinical research is expected to boost market growth over the forecast period.The AI in clinical trials market is expected to witness significant growth over the next few years. The need to reduce costs and improve efficiency associated with clinical trials is driving increased adoption of AI solutions. Additionally, government initiatives and investments to support the integration of AI in healthcare are also fueling the market trend. Advanced algorithms are helping clinical researchers in various areas including patient recruitment, drug discovery and personalized treatment.